CION Ameerpet
If you have gone through the menopause and you are bleeding, please book an appointment rather than reading further. Most causes are benign and treatable — but this is the one gynaecological symptom that should never be watched and waited on.
Once you have gone twelve months without a period, you are post-menopausal, and the uterine lining should not bleed again. Any bleeding after that point — a single episode of spotting, a pink or brown discharge, bleeding after sex, or something heavier — is treated as a symptom requiring assessment. Not because it is usually dangerous, but because the rule is simple and the alternative is worse.
The reassuring part: the great majority of post-menopausal bleeding turns out to be benign. Vaginal and endometrial atrophy — thinning and fragility of the tissues from low oestrogen — is the commonest cause by far, and it is easily treated. Endometrial and cervical polyps are next, and they are removable. Hormone therapy accounts for a further share.
The reason for the rule is that post-menopausal bleeding is the cardinal symptom of endometrial cancer, and that is the more relevant concern here than ovarian cancer. Endometrial cancer is one of the more common gynaecological cancers, and it usually announces itself early through exactly this symptom — which is why it is frequently caught at a highly treatable stage. Ovarian cancer is a much less common cause of bleeding. See endometrial cancer.
Spotting counts. A pink discharge counts. A single episode counts. There is no threshold below which post-menopausal bleeding is ignored.
Vaginal atrophy and polyps between them explain the large majority. Both are straightforwardly treatable once identified.
Post-menopausal bleeding is the cardinal symptom of endometrial cancer. Ovarian cancer is a much less common cause of it.
Postmenopausal bleeding is one of the few gynaecological symptoms with a near-universal referral rule: every episode is investigated regardless of how light or how brief. The reason is that it is the presenting symptom in the great majority of endometrial cancers, and endometrial cancer found at an early stage — while still confined to the uterus — has a substantially better outlook than one found late. The rule exists precisely because most bleeding is benign: applying it universally is what makes the small number of important cases turn up early. Source: NCCN Uterine Neoplasms guidelines; standard gynaecological practice.
Roughly in order of how often they turn out to be the answer. The first three account for most cases.
The commonest cause. After the menopause, falling oestrogen thins the vaginal and endometrial tissues, making them fragile and prone to light bleeding — often after sex, or spontaneously as spotting. It is frequently accompanied by vaginal dryness, itching, discomfort during intercourse and urinary symptoms.
It is diagnosed on examination and confirmed when a scan shows a thin endometrium. It responds very well to topical vaginal oestrogen, which acts locally with minimal systemic absorption. It is common, benign and genuinely improvable — many women put up with it for years before mentioning it.
Benign overgrowths of the uterine lining or the cervix. They are common after the menopause, they bleed unpredictably because their surface is fragile, and they often produce exactly the intermittent light spotting that brings women to the clinic.
They are identified on transvaginal ultrasound or hysteroscopy and removed as a short procedure, which both stops the bleeding and allows the tissue to be examined. A small proportion of polyps contain abnormal cells, which is why removal and examination is preferred to leaving them in place.
Menopausal hormone therapy commonly causes bleeding, particularly in the first months of a new regimen or after a change in dose. Sequential regimens produce planned monthly bleeding by design; continuous combined regimens should settle to no bleeding after the first several months.
Bleeding that is unscheduled, that starts after a previously settled period on the same regimen, or that continues beyond the expected settling-in phase is not simply assumed to be the hormones. It is investigated in the same way as any other post-menopausal bleeding.
Thickening of the uterine lining, driven by oestrogen unopposed by progestogen. It is more common with obesity, because fat tissue produces oestrogen, and with diabetes and polycystic ovary syndrome. It causes irregular bleeding and is identified on ultrasound and endometrial sampling.
It matters because some forms — particularly hyperplasia with atypia — can progress to endometrial cancer if untreated. Identified early it is very treatable, with hormonal treatment or surgery depending on the type and on individual circumstances. See endometrial hyperplasia.
The most important cause to exclude, and the reason the referral rule exists. It presents with post-menopausal bleeding in the great majority of cases, which is fortunate: the symptom appears while the disease is often still confined to the uterus and highly treatable.
Risk is increased by obesity, diabetes, late menopause, never having been pregnant, unopposed oestrogen, and Lynch syndrome. It is identified with transvaginal ultrasound measuring endometrial thickness followed by endometrial sampling, and the pathway is quick.
A much less common cause of post-menopausal bleeding. Certain ovarian tumours — particularly granulosa cell tumours and some other sex-cord stromal types — produce oestrogen, which stimulates the endometrium and causes bleeding. In these cases the bleeding is a secondary consequence rather than a direct one.
This is why the assessment does not stop at the uterus: the ovaries are examined on the same transvaginal scan. Where the endometrial work-up is normal but bleeding continues, or where an adnexal mass is seen, the ovaries move to the centre of the picture.
All post-menopausal bleeding warrants assessment. These features mean arranging it promptly rather than at your convenience.
Bleeding comparable to a period, or heavier, in a woman who has been post-menopausal for years, should be assessed without delay.
Repeated episodes, or bleeding that continues over weeks, carries more weight than a single brief episode of spotting.
Pelvic pain alongside bleeding broadens the assessment beyond the endometrium alone.
Persistent bloating or genuine abdominal enlargement with bleeding warrants assessment of the ovaries as well as the uterus.
Losing weight without trying, alongside post-menopausal bleeding, always warrants prompt assessment.
This raises the possibility of Lynch syndrome, which increases the risk of both endometrial and ovarian cancer. See hereditary risk.
The general standard is to be seen within about two weeks of reporting post-menopausal bleeding. If you have been offered a much longer wait, it is reasonable to ask for that to be reviewed.
Not because it is usually serious — it usually is not — but because the small proportion that matters is highly treatable when caught early, and the assessment is quick.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Most post-menopausal bleeding has a benign, easily treated cause — and all of it deserves to be checked.
The pathway is short, well-established and usually completed in one or two visits. Knowing its shape removes most of the dread.
When the bleeding occurred, how much, how many episodes, how long since your last period, whether you are on hormone therapy, and whether there is pain, bloating, weight loss or discharge. A speculum examination looks at the cervix and vagina directly and frequently identifies atrophy or a visible polyp on the spot.
The key first test. It measures the thickness of the endometrium — a thin lining makes endometrial cancer very unlikely, while a thickened one directs the next step — and it assesses the ovaries at the same time. It is quick, painless and radiation-free, and for many women it is where the pathway effectively ends.
Where the endometrium is thickened, where bleeding recurs, or where risk factors are present, a small sample of the uterine lining is taken. A pipelle sample is an outpatient procedure taking a few minutes, with cramping similar to period pain. It gives a definitive tissue diagnosis.
A thin camera passed into the uterus allows the lining to be inspected directly and any polyp to be removed at the same time. It is used where a sample was inadequate, where a polyp is suspected, or where bleeding continues despite normal earlier tests.
The ovaries are assessed on the same transvaginal scan. Where an adnexal mass is seen, or where bleeding persists with a normal endometrial work-up, a CA-125 is interpreted alongside imaging and further imaging may follow. See reading a CA-125.
Atrophy is treated with topical oestrogen. Polyps are removed. Hyperplasia is treated hormonally or surgically depending on type. Where a gynaecological cancer is identified, care moves to a specialist pathway with a tumour-board discussion; at CION, chemotherapy and maintenance treatment are delivered in-house, while gynaecologic-oncology surgery is coordinated with specialist partner centres and may be billed there.
The most common reason post-menopausal bleeding gets delayed is that it was light and brief, and it did not seem worth troubling anyone about. A single episode of spotting that stopped the same day feels like nothing. It is still the symptom that warrants assessment, and the assessment is quick — often a single scan.
Your first consultation at CION is free and runs to about 45 minutes. We will be clear that for this symptom the primary question is the uterus rather than the ovaries: post-menopausal bleeding is the cardinal symptom of endometrial cancer, and the assessment is built around excluding that first. The ovaries are examined on the same scan, so nothing is missed either way.
Where the assessment does find a gynaecological cancer, CION delivers medical oncology in-house — chemotherapy and maintenance therapy across 35+ centres in Telangana and Andhra Pradesh — alongside genetic counselling, which matters here because a family history of endometrial and bowel cancer raises the question of Lynch syndrome. Gynaecologic-oncology surgery is coordinated with specialist partner centres and may be billed there. We state that upfront.
The standard for post-menopausal bleeding is assessment within about two weeks. It is a short pathway and it should not be a slow one.
For this symptom the endometrium is the primary concern, not the ovaries. We assess it that way while examining the ovaries on the same scan.
A family history of endometrial and bowel cancer raises the possibility of Lynch syndrome, which affects ovarian risk too. Counselling is available at CION.
Assessment, follow-up and any chemotherapy near where you live across Telangana and Andhra Pradesh.
No — the great majority of it turns out to be benign. Vaginal and endometrial atrophy, which is thinning and fragility of the tissues caused by low oestrogen, is the commonest cause by a wide margin, followed by endometrial and cervical polyps and the effects of hormone therapy. All of these are treatable, most of them straightforwardly. But every episode is still investigated, because post-menopausal bleeding is the cardinal symptom of endometrial cancer, and applying the rule universally is exactly what allows those cases to be found early, while the disease is often still confined to the uterus and highly treatable.
Any amount counts, and a single brief episode counts. Light spotting, a pink or brown vaginal discharge, a small amount of blood noticed only on wiping, or bleeding after sex all meet the definition of post-menopausal bleeding and all warrant assessment. There is no threshold below which it is safely ignored. This is worth stressing because the commonest reason for delay is precisely that the bleeding was light and stopped on its own, which makes it feel like nothing worth mentioning. The assessment is quick — often a single scan — so the cost of checking is low.
It can be, but it is much less common. Post-menopausal bleeding points primarily at the uterus, and endometrial cancer is the main concern the assessment is designed around. Where ovarian cancer causes bleeding, it is usually indirect: certain ovarian tumours, particularly granulosa cell and some other sex-cord stromal types, produce oestrogen which stimulates the uterine lining and causes it to bleed. This is one reason the ovaries are examined on the same transvaginal scan used to measure the endometrium, so both questions are answered in a single test.
Yes, though the interpretation depends on your regimen and timing. Sequential hormone therapy produces planned monthly bleeding by design, and that is expected. Continuous combined therapy commonly causes unpredictable bleeding in the first months and should then settle. What is not simply attributed to the hormones is bleeding that is unscheduled, that begins after you had previously settled on the same regimen, or that continues beyond the expected settling-in phase. In those situations the bleeding is investigated in the same way as in any other post-menopausal woman, rather than assumed to be a side effect.
It is the key measurement from the transvaginal ultrasound and it directs everything that follows. The endometrium is the lining of the uterus, and after the menopause it should be thin. A thin lining makes endometrial cancer very unlikely and, in a woman with a single episode of bleeding and no risk factors, often means no further testing is needed. A thickened lining does not mean cancer — hyperplasia, polyps and hormone effects all thicken it — but it does mean a tissue sample is taken so the cause can be identified definitively rather than inferred from a measurement.
The general standard is assessment within about two weeks of reporting post-menopausal bleeding, and it is reasonable to ask for that if you have been offered a much longer wait. Move faster if the bleeding is heavy, comparable to a period or greater, if it keeps recurring, or if it comes with pelvic pain, persistent bloating, a genuinely enlarging abdomen or unintended weight loss. You do not need emergency care for light spotting, but you should not put off booking either — this is the one gynaecological symptom where watchful waiting is not the right approach.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology in-house, covering chemotherapy and maintenance treatment across more than 35 centres in Telangana and Andhra Pradesh, alongside genetic counselling — which is particularly relevant here, because a family history of endometrial and bowel cancer raises the possibility of Lynch syndrome, affecting both endometrial and ovarian risk. Gynaecologic-oncology surgery is coordinated with specialist partner centres and may be billed there, and we state that upfront rather than leaving it to be discovered later.